This database contains 32 studies, archived under the term: "Huntingtons"
Click here to filter this large number of results.
Cognitive function in early clinical phase huntington disease after rivastigmine treatment
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]
PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease
Rosas, H. D.,
Doros, G.,
Gevorkian, S.,
Malarick, K.,
Reuter, M.,
Coutu, J.-P.,
Triggs, T. D.,
Wilkens, P. J.,
Matson, W.,
Salat, D. H.,
Hersch, S. M.
Objective: To assess the safety and tolerability of high-dose creatine, the feasibility of enrolling premanifest and 50% at-risk subjects in a prevention trial, and the potential of cognitive, imaging, and blood markers.; Methods: Sixty-four eligible consenting participants were randomly allocated (1:1) to 15 g twice daily of creatine monohydrate or placebo for a 6-month double-blind […]
Task-specific training in Huntington disease: a randomized controlled feasibility trial
Quinn, L.,
Debono, K.,
Dawes, H.,
Rosser, A. E.,
Nemeth, A. H.,
Rickards, H.,
Tabrizi, S. J.,
Quarrell, O.,
Trender-Gerhard, I.,
Kelson, M. J.,
Townson, J.,
Busse, M.
Background: Task-specific training may be a suitable intervention to address mobility limitations in people with Huntington disease (HD).; Objective: The aim of this study was to assess the feasibility and safety of goal-directed, task-specific mobility training for individuals with mid-stage HD.; Design: This study was a randomized, blinded, feasibility trial; participants were randomly assigned to […]
Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study
Paulsen, Jane S.,
Long, Jeffrey D,
Ross, Christopher A,
Harrington, Deborah L,
Erwin, Cheryl J,
Williams, Janet K,
Westervelt, Holly James,
Johnson, Hans J,
Aylward, Elizabeth H,
Zhang, Ying,
Bockholt, H Jeremy,
Barker, Roger A
Background: Although the association between cytosine-adenine-guanine (CAG) repeat length and age at onset of Huntington’s disease is well known, improved prediction of onset would be advantageous for clinical trial design and prognostic counselling. We compared various measures for tracking progression and predicting conversion to manifest Huntington’s disease.; Methods: In this prospective observational study, we assessed […]
Fetal striatal grafting slows motor and cognitive decline of Huntington’s disease
Paganini, M.,
Biggeri, A.,
Romoli, A. M.,
Mechi, C.,
Ghelli, E.,
Berti, V.,
Pradella, S.,
Bucciantini, S.,
Catelan, D.,
Saccardi, R.,
Lombardini, L.,
Mascalchi, M.,
Massacesi, L.,
Porfirio, B.,
Di Lorenzo, N.,
Vannelli, G. B.,
Gallina, P.
Objective: To assess the clinical effect of caudate-putaminal transplantation of fetal striatal tissue in Huntington’s disease (HD).; Methods: We carried out a follow-up study on 10 HD transplanted patients and 16 HD not-transplanted patients. All patients were evaluated with the Unified HD Rating Scale (UHDRS) whose change in motor, cognitive, behavioural and functional capacity total […]
Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington’s disease
Lundin, Anders,
Dietrichs, Espen,
Haghighi, Sara,
Göller, Marie-Louise,
Heiberg, Arvid,
Loutfi, Ghada,
Widner, Håkan,
Wiktorin, Klas,
Wiklund, Leif,
Svenningsson, Anders,
Sonesson, Clas,
Waters, Nicholas,
Waters, Susanna,
Tedroff, Joakim
Objectives: To evaluate the efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington’s disease (HD).; Methods: In a randomized, double-blind, placebo-controlled, 4-week trial, patients with HD received pridopidine (50 mg/d, n = 28) or placebo (n = 30). The primary outcome measure was the change from baseline in weighted cognitive score, […]
What effect does a structured home-based exercise programme have on people with Huntington’s disease? A randomized, controlled pilot study
Khalil, H.,
Quinn, L.,
van Deursen, R.,
Dawes, H.,
Playle, R.,
Rosser, A.,
Busse, M.
Objective: The aim of this study was to explore feasibility, safety and outcome of an exercise intervention in people with Huntington’s disease.; Design: A randomized controlled pilot trial.; Setting: A home-based exercise programme.; Subjects: A total of 25 subjects with early to mid-stage Huntington’s disease.; Intervention: Subjects were randomly allocated to either an exercise intervention […]
Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: A phase 2, randomised, double-blind, placebo-controlled trial
Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]